top of page

Publications

Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice

Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG.

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky VS, Yeung MS, Zagorski CM, Reveles KR.

Description and Evaluation of a Pilot Advanced Pharmacy Practice Experience in Addiction Medicine

Loera LJ, Hill LG, Zagorski CM, Jermain ML, Tirado CF.

Increasingly powerful opioid antagonists are not necessary

Hill LG, Zagorski CM, Loera LJ.

Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.

White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.

Naloxone counseling for harm reduction and patient engagement

Han JK, Hill LG, Koenig ME, Das N.

Operation Naloxone: Overdose prevention service learning for student pharmacists

Hill LG, Sanchez JP, Laguado SA, Lawson KA.

Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas

Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR.

State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility

Hill LG, Reveles KR, Evoy KE.

Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction

Hill LG, Evoy KE, Reveles KR.

bottom of page